REG - SkinBioTherapeutics - Notice of AGM and posting of Annual Report

SkinbiotherapeuticsAnnouncement

06/12/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231206:nRSF7397Va&default-theme=true

RNS Number : 7397V  SkinBioTherapeutics PLC  06 December 2023

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

Posting of Annual Report and AGM Notice

 

6 December 2023 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the
life science business focused on skin health confirms that the Notice of
Annual General Meeting ("AGM"), form of proxy and Annual Report and Accounts
for the year ended 30 June 2023 have been posted to shareholders.

 

An electronic copy of the Annual Report and Accounts and the Notice of AGM are
also available on the Company's website
- www.skinbiotherapeutics.com/investor-relations
(http://www.skinbiotherapeutics.com/investor-relations) .

 

The AGM will be held at 9:00am on Friday 29 December 2023 at The Clarion
Hotel, Witney Way, Boldon, NE35 9PE.

 

-Ends-

 

For more information please contact:

 

 SkinBioTherapeutics plc                     Tel: +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited           Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson

(Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Instinctif Partners (financial press)       Tel: +44 (0) 20 7457 2020

 Melanie Toyne-Sewell / Jack Kincade         SkinBioTherapeutics@instinctif.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAUVVRROWUURAA